| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1998;29:2587-2599.)
© 1998 American Heart Association, Inc.
Original Contributions |
Diffusion-Weighted Magnetic Resonance Imaging Confirms Marked Neuroprotective Efficacy of Albumin Therapy in Focal Cerebral Ischemia
From the Cerebral Vascular Disease Research Center, Department of Neurology (L.B., W.Z., P.W.H., B.L., R.B., M.D.G.), and Department of Radiology (P.M.P., R.G.W.), University of Miami School of Medicine, Miami, Fla.
Background and Purpose—We have recently shown high-dose human serum albumin therapy to confer marked histological protection in experimental middle cerebral artery occlusion (MCAo). We have now used diffusion-weighted magnetic resonance imaging (DWI) in conjunction with morphological methods to expand our understanding of this therapeutic approach.
Methods—Physiologically controlled Sprague-Dawley rats received 2-hour MCAo by the modified intraluminal suture method. Treated rats received 25% human serum albumin solution (1% by body weight) immediately after the MCA was reopened. Vehicle-treated rats received saline. Computer-based image averaging was used to analyze DWI data obtained 24 hours after MCAo and light-microscopic histopathology obtained at 3 days. In a matched series, plasma osmolality and colloid oncotic pressure, as well as brain water content, were determined.
Results—Albumin therapy, which lowered the hematocrit on average by 37% and raised plasma colloid oncotic pressure by 56%, improved the neurological score throughout the 3-day survival period. Within the ischemic focus, the apparent diffusion coefficient (ADC) computed from DWI data declined by 40% in vehicle-treated rats but was preserved at near-normal levels (8% decline) in albumin-treated rats (P<0.001). Albumin also led to higher ADC values within unlesioned brain regions. Histology revealed large consistent cortical and subcortical infarcts in vehicle-treated rats, while albumin therapy reduced infarct volume at these sites, on average, by 84% and 33%, respectively. Total infarct volume was reduced by 66% and brain swelling was virtually eliminated by albumin treatment. Microscopically, while infarcted regions of vehicle-treated rats had the typical changes of pannecrosis, infarcted zones of albumin-treated brains showed persistence of vascular endothelium and prominent microglial activation, suggesting that albumin therapy may help to preserve the neuropil within zones of residual infarction.
Conclusions—These findings confirm the striking neuroprotective efficacy of albumin therapy in focal cerebral ischemia and reveal that this effect is associated with DWI normalization and a mitigation of pannecrotic changes within zones of residual injury.
Editorial Comment
Department of Radiology
Anesthesiology/Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland
This article has been cited by other articles:
 |
|
 |
|
  H.-P. Park, A. Nimmagadda, R. A. DeFazio, R. Busto, R. Prado, and M. D. Ginsberg Albumin Therapy Augments the Effect of Thrombolysis on Local Vascular Dynamics in a Rat Model of Arteriolar Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, May 1, 2008; 39(5): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nimmagadda, H.-P. Park, R. Prado, and M. D. Ginsberg Albumin Therapy Improves Local Vascular Dynamics in a Rat Model of Primary Microvascular Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, January 1, 2008; 39(1): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg and M. D. Hill Response to Letter by Parkkinen et al Stroke, February 1, 2007; 38(2): 256 - 256. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg, M. D. Hill, Y. Y. Palesch, K. J. Ryckborst, and D. Tamariz The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--I: Physiological Responses and Safety Results Stroke, August 1, 2006; 37(8): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Palesch, M. D. Hill, K. J. Ryckborst, D. Tamariz, and M. D. Ginsberg The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--II: Neurologic Outcome and Efficacy Analysis Stroke, August 1, 2006; 37(8): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, I. Saul, R. Busto, K. Danielyan, A. Vigdorchik, L. Khoutorova, and M. D. Ginsberg Albumin Treatment Reduces Neurological Deficit and Protects Blood-Brain Barrier Integrity After Acute Intracortical Hematoma in the Rat Stroke, February 1, 2005; 36(2): 326 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, V. L. Marcheselli, L. Khoutorova, E. B. Rodriguez de Turco, R. Busto, M. D. Ginsberg, and N. G. Bazan Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection Stroke, January 1, 2005; 36(1): 118 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Dziedzic, A. Slowik, and A. Szczudlik Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, June 1, 2004; 35(6): e156 - e158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Gum, R. A. Swanson, C. Alano, J. Liu, S. Hong, P. R. Weinstein, and S. S. Panter Human Serum Albumin and its N-Terminal Tetrapeptide (DAHK) Block Oxidant-Induced Neuronal Death Stroke, February 1, 2004; 35(2): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Nohe and H.-J. Dieterich A different view on human albumin Cardiovasc Res, June 1, 2003; 58(3): 721 - 722. [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, L. Khoutorova, T. A. Deisher, A. Belayev, R. Busto, Y. Zhang, W. Zhao, and M. D. Ginsberg Neuroprotective Effect of SolCD39, a Novel Platelet Aggregation Inhibitor, on Transient Middle Cerebral Artery Occlusion in Rats Stroke, March 1, 2003; 34(3): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Muchitsch, H. P. Schwarz, M. D. Ginsberg, L. Belayev, and R. Busto Beneficial Effect of Albumin Therapy Attributable to {alpha}1-Acid Glycoprotein? Stroke, January 1, 2003; 34(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Adventures in the Pathophysiology of Brain Ischemia: Penumbra, Gene Expression, Neuroprotection: The 2002 Thomas Willis Lecture Stroke, January 1, 2003; 34(1): 214 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Zhang and B. Frei Albumin selectively inhibits TNF{alpha}-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells Cardiovasc Res, September 1, 2002; 55(4): 820 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, E. Pinard, H. Nallet, J. Seylaz, Y. Liu, P. Riyamongkol, W. Zhao, R. Busto, and M. D. Ginsberg Albumin Therapy of Transient Focal Cerebral Ischemia: In Vivo Analysis of Dynamic Microvascular Responses Stroke, April 1, 2002; 33(4): 1077 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, Y. Liu, W. Zhao, R. Busto, and M. D. Ginsberg Human Albumin Therapy of Acute Ischemic Stroke : Marked Neuroprotective Efficacy at Moderate Doses and With a Broad Therapeutic Window Stroke, February 1, 2001; 32(2): 553 - 560. [Abstract] [Full Text] [PDF]
|
|